Long‐Term Pooled Safety Analysis of Palbociclib in Combination with Endocrine Therapy for Hormone Receptor‐Positive/Human Epidermal Growth Factor Receptor 2‐Negative Advanced Breast Cancer: Updated Analysis with up to 5 Years of Follow‐Up

BACKGROUND: Previous studies demonstrated the tolerability of palbociclib plus endocrine therapy (ET). This analysis evaluated safety based on more recent cutoff dates and a longer palbociclib treatment exposure. PATIENTS AND METHODS: Data were pooled from three randomized studies of patients with h...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Oncologist
Main Authors: Finn, Richard S., Rugo, Hope S., Gelmon, Karen A., Cristofanilli, Massimo, Colleoni, Marco, Loi, Sherene, Schnell, Patrick, Lu, Dongrui R., Theall, Kathy Puyana, Mori, Ave, Gauthier, Eric, Bananis, Eustratios, Turner, Nicholas C., Diéras, Véronique
Formato: Artigo
Idioma:Inglês
Publicado: John Wiley & Sons, Inc. 2021
Assuntos:
Breast Cancer
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC8100571/
https://ncbi.nlm.nih.gov/pubmed/33486783
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/onco.13684
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares